Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 04 Mar 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary) ; Quaratusugene ozeplasmid (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Diphenhydramine; Paracetamol; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Acclaim-1
  • Sponsors Genprex

    • Most Recent Events

    • 05 Feb 2024 According to a Genprex media release, interim analysis from the Phase 2a study is expected in 2025 and these results will further validate novel gene therapy approach to treating lung cancer patients.
    • 05 Feb 2024 According to a Genprex media release, company announced that in January 2024, the first patient was enrolled and dosed in the Phase 2a expansion portion of the Acclaim-1 study.
    • 05 Jan 2024 According to a Genprex Media Release, in January 2024, Genprex expects to open the Phase 2a expansion portion of the Acclaim-1 study for enrollment, Genprex expects to complete the enrollment of 19 patients in each cohort of the Phase 2a expansion portion of the study by the end of 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top